Therefore, future studies could further validate the KC-intrinsic immune regulatory mechanism mediated by SULT2B1 through perturbation experiments, such as using KC-specific Sult2b1 knockout or overexpression mice, or introducing Sult2b1 mRNA/siRNA into skin KCs via drug delivery systems. This evidence concerns the gene SULT2B1 and dry eye syndrome.